The mission of Institute QuantiVision (iQ) is to develop medical imaging devices, software and protocols to enhance the efficiency, efficacy and economy of healthcare in the Netherlands, with focus on oncology and neurology. In particular, starting from clinical questions, iQ will develop high quality medical devices and protocols for quantitative analysis and integration of images at microscopic and macroscopic scale in order to improve diagnosis and therapy.
Healthcare improvement will be achieved by increasing diagnostic sensitivity, improving disease monitoring, improving localization of therapy, and improving evaluation of response to therapy.
To complete our mission, we aim to:
- enable better, faster, and more affordable diagnosis and monitoring of patients.
- improve therapeutic imaging support and enable image-guided optical biopsies that are more reliable, time-efficient, less invasive than standard tissue biopsies.
- develop sophisticated data reduction and feature extraction methods, so that healthcare professionals can make optimal use of all available data without suffering from data overflow.
- disseminate developed knowledge by education and devices and protocols in collaboration with industry, both nationally and internationally.
Aims and objectives
Starting from clinical questions, iQ will develop optical imaging devices, software and protocols to enhance efficiency, efficacy and economy of healthcare in the Netherlands, focusing on oncology and neurology. In particular, iQ aims at quantitative analysis and integration of images at a microscopic and macroscopic scale. Healthcare improvements will be made by enabling individualized and therefore optimized treatment. This will be achieved by quantitative analysis of multidimensional images, resulting in increased diagnostic sensitivity, improved monitoring of disease, improved monitoring of response to therapy and optimized therapy through image guided interventions. Devices, software and protocols developed within iQ will validated in clinical studies and will be disseminated both nationally and internationally in collaboration with industry.
IQ’s approach leads to increased efficiency in healthcare, improved diagnosis, new therapies, shorter treatment times for patients and practical solutions that will be adopted by industry and implemented in healthcare more quickly. Successful business developments and valorization are essential to iQ. As iQ focuses on translational research, clinically validated algorithms resulting from iQ will be of high healthcare and economical value. The work of the consortium will optimize quality and exchangeability of imaging equipment, which improves scientific accuracy and significance of findings obtained with this equipment. One of the main benefits of iQ will be that only those patients who will actually benefit will be selected for an (expensive) treatment, whilst non-responders can be offered alternative therapies without delay and without first suffering unnecessary toxicity as a result of ineffective therapy. Benefits will not only be experienced by healthcare professionals and their patients, but will also support the long-term (inter)national competitiveness of Dutch Industry and Science.
IQ aims to revolutionize the future of clinical practice, by enabling better, faster, and more affordable diagnosis and monitoring of patients. iQ developments will focus on clinical usefulness. As developments will be based on clinical needs, progress will be driven by a “clinical pull” rather than a “research push”, making sure that result of iQ are relevant for daily clinical practice. In ten years, iQ will have reached almost 75 milestones and deliveries in the area of image processing software, diagnostic and prognostic biomarkers, multi-purpose catheters, detection of neoplastic tissue, and (laser) microscopy.